 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...145146147148149150151152153154155...235236» |
- | Enrollment closed: A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 1, 2020
P2, N=39, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting
- |||| Graspa (eryaspase) / PHAXIAM Therap
Trial completion date, Trial primary completion date, Combination therapy: Trybeca-1: Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (clinicaltrials.gov) - Sep 29, 2020
P3, N=500, Recruiting, Sponsor: ERYtech Pharma
Recruiting --> Active, not recruiting Trial completion date: Apr 2021 --> Oct 2021 | Trial primary completion date: Aug 2020 --> Dec 2020
- | New P2 trial, Metastases: GABRINOX-ART: Sequential Treatment with GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients with Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Sep 29, 2020
P2, N=103, Not yet recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
- | veliparib (ABT-888) / AbbVie
Trial completion date, PARP Biomarker: S1513: FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Sep 28, 2020
P2, N=123, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Apr 2021 --> Oct 2021 | Trial primary completion date: Aug 2020 --> Dec 2020 Trial completion date: May 2020 --> Oct 2020
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: (clinicaltrials.gov) - Sep 28, 2020
P2, N=28, Recruiting, Sponsor: Big Ten Cancer Research Consortium
Trial completion date: May 2020 --> Oct 2020 Not yet recruiting --> Recruiting | Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2021 --> Sep 2022
- [VIRTUAL] NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. () - Sep 27, 2020 - Abstract #COSA2020COSA_319;
P3
Patients will continue treatment until disease progression, unacceptable toxicity or study withdrawal, and will then be followed for survival every 2-months until death or study-end (when all patients have died, withdrawn consent or lost to follow-up). This study is funded by Ipsen.
- leucovorin calcium / Generic mfg.
[VIRTUAL] Addition of netupitant to 5HT3-receptor antagonist/dexamethasone prophylaxis with FOLFOX reduces rates of chemotherapy-induced nausea and vomiting (CINV). () - Sep 27, 2020 - Abstract #COSA2020COSA_348;
Discussion With upfront triple-therapy prophylaxis, there was a statistically significant reduction in both nausea and vomiting. Triple-therapy prophylaxis with netupitant-palonosetron-dexamethasone should be considered for patients receiving FOLFOX chemotherapy, where there are no major contraindications.
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
[VIRTUAL] Real-world tolerance and outcomes to oxaliplatin-based adjuvant chemotherapy for stage III colon cancer - does dose intensity matter? () - Sep 27, 2020 - Abstract #COSA2020COSA_261;
Patients receiving CAPOX had more grade ≥2 diarrhoea (p=0.016) and hand-foot syndrome (p<0.001) but not peripheral neuropathy, myelosuppression or fatigue. Conclusions : In a real-world setting, despite less chemotherapy being administered in those receiving CAPOX, they had better DFS when compared to FOLFOX in the adjuvant setting.
- oxaliplatin / Generic mfg., Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
[VIRTUAL] First-line liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: results from a phase 1/2 study () - Sep 27, 2020 - Abstract #COSA2020COSA_418;
P1/2, P3
This study is funded by Ipsen. This abstract was originally presented virtually at the 2020 ESMO World Congress on Gastrointestinal Cancer.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal, MSi-H Biomarker: ERCC overexpression associated with a poor response of cT4b colorectal cancer with FOLFOX-based neoadjuvant concurrent chemoradiation. (Pubmed Central) - Sep 25, 2020
Due to their poor response to concurrent chemoradiation (CCRT) with FOLFOX, the chemotherapy regimen was changed to irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as the second-line neoadjuvant treatment...The present study indicated that ERCC overexpression associated with the poor response of FOLFOX-based CCRT and FOLFIRI after FOLFOX-based CCRT failure may have a potential role in conversion to resectable tumors by neoadjuvant treatment in cT4b CRC. However, a further prospective study with more patients is required to improve the precision of the conclusions.
- | Trial completion date, Metastases: Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer (clinicaltrials.gov) - Sep 25, 2020
P2, N=50, Active, not recruiting, Sponsor: Massachusetts General Hospital
However, a further prospective study with more patients is required to improve the precision of the conclusions. Trial completion date: Aug 2020 --> Sep 2021
- Xpovio (selinexor) / Ono Pharma, Karyopharm, Antengene
[VIRTUAL] Selinexor in combination with standard chemotherapy in patients with advanced solid tumours: Results of an open label, single:center, multi-arm phase Ib study (Channel 4) - Sep 24, 2020 - Abstract #ESMOAsia2020ESMO_Asia_67;
P1
Funding: Karyopharm. Clinical trial identification: NCT02419495.
- || leucovorin calcium / Generic mfg.
Clinical, Journal: Accidental High Dose Intrathecal Treatment - Late Result of A Patient (Pubmed Central) - Sep 24, 2020
Clinical trial identification: NCT02419495. No abstract available
- | dactinomycin / Generic mfg.
New trial: Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia (clinicaltrials.gov) - Sep 23, 2020
P=N/A, N=176, Not yet recruiting, Sponsor: xiang yang
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., paclitaxel / Generic mfg.
Clinical, Journal: Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer. (Pubmed Central) - Sep 23, 2020
The most common grade 3-4 toxicities included leukopenia (16.8%), neutropenia (17.7%), anemia (8.0%), thrombocytopenia (5.3%), and fatigue (6.2%). Combination chemotherapy with TFL offers an active and safe therapeutic approach for patients with AGC.
- | Journal: 5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy. (Pubmed Central) - Sep 23, 2020
Thereafter, the patient was rechallenged successfully by the same chemotherapy regimen (FOLFIRINOX) for more than 6 months with a protocol consisting in a free protein diet, and administration of ammonium chelators, and Krebs and urea cycle intermediates, to prevent further hyperammonemia. We also present a review of the literature on 5-FU rechallenge after 5-FU-induced hyperammonemic encephalopathy.
- || fluorouracil / Generic mfg., Stivarga (regorafenib) / Bayer, irinotecan / Generic mfg.
Clinical, Journal: Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial. (Pubmed Central) - Sep 22, 2020
P2
Dose adjustment for regorafenib and irinotecan makes treatment-related AEs tolerable and makes the concomitant treatment practicable. This study will provide initial evidence regarding the efficacy and safety of a new combination of chemotherapy and a targeted agent for mCRC.
- |||| Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial completion date, Trial primary completion date, Metastases: Avenger 500: Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Sep 21, 2020
P3, N=500, Recruiting, Sponsor: Rafael Pharmaceuticals Inc.
This study will provide initial evidence regarding the efficacy and safety of a new combination of chemotherapy and a targeted agent for mCRC. Trial completion date: Mar 2022 --> Jun 2021 | Trial primary completion date: Oct 2021 --> Mar 2021
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Clinical, Review, Journal: Neoadjuvant chemotherapy for gastric cancer. Frequent overtreatment or meaningful concept? (Pubmed Central) - Sep 21, 2020
This article critically deals with the current state of the art concepts as well as with ongoing studies with respect to neoadjuvant and perioperative treatment of gastric cancer. For this purpose, the essential already published and the active studies are presented.
- ||| Clinical, P3 data, Retrospective data, Clinical Trial,Phase III, Journal: Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study. (Pubmed Central) - Sep 20, 2020
The median overall survival (OS) was 26.2 and 35.5 months, respectively (log-rank, P = .062). According to univariate analysis, morphologic response was not associated with PFS or OS, whereas RECIST response was significantly associated with both PFS and OS, with ETS and DpR being associated with significantly longer PFS.Morphologic response might be neither a predictive nor a prognostic factor in patients with CLM undergoing chemotherapy containing bevacizumab, whereas RECIST response was significantly associated with both PFS and OS.
- | Trial completion date, Trial primary completion date, Combination therapy: Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2020
P1, N=38, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
According to univariate analysis, morphologic response was not associated with PFS or OS, whereas RECIST response was significantly associated with both PFS and OS, with ETS and DpR being associated with significantly longer PFS.Morphologic response might be neither a predictive nor a prognostic factor in patients with CLM undergoing chemotherapy containing bevacizumab, whereas RECIST response was significantly associated with both PFS and OS. Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
- | oleclumab (MEDI9447) / AstraZeneca, monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Trial withdrawal, Combination therapy: Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC (clinicaltrials.gov) - Sep 19, 2020
P2, N=0, Withdrawn, Sponsor: MedImmune LLC
Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021 N=160 --> 0 | Not yet recruiting --> Withdrawn
- || Clinical, P2 data, Journal: Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802). (Pubmed Central) - Sep 18, 2020
N=160 --> 0 | Not yet recruiting --> Withdrawn Weekly 5-FU-leucovorin with biweekly bevacizumab may be a tolerable and effective treatment option for older or frail patients with mCRC.
- || Clinical, P2 data, Journal: Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial. (Pubmed Central) - Sep 18, 2020
Weekly 5-FU-leucovorin with biweekly bevacizumab may be a tolerable and effective treatment option for older or frail patients with mCRC. Our results show that the 24h-SIRI/B regimen is an effective and reasonably well-tolerated regimen for the first-line treatment of mCRC.
- || Trial primary completion date, Metastases: QUILT-3.071: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (clinicaltrials.gov) - Sep 17, 2020
P1b/2, N=332, Active, not recruiting, Sponsor: NantKwest, Inc.
Our results show that the 24h-SIRI/B regimen is an effective and reasonably well-tolerated regimen for the first-line treatment of mCRC. Trial primary completion date: Dec 2019 --> Dec 2021
- | Erbitux (cetuximab) / Eli Lilly
New P2 trial, Liquid biopsy, Tumor mutational burden, Metastases, Biopsy: MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab (clinicaltrials.gov) - Sep 17, 2020
P2, N=144, Not yet recruiting, Sponsor: TheraOp
- ||| aplitabart (IGM-8444) / IGM Biosciences
New P1 trial, Combination therapy: IGM-8444-001: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers (clinicaltrials.gov) - Sep 16, 2020
P1, N=230, Recruiting, Sponsor: IGM Biosciences, Inc.
- || leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical data, Retrospective data, Journal, Microsatellite instability: Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. (Pubmed Central) - Sep 16, 2020
The addition of cetuximab to adjuvant FOLFOX was associated with shorter DFS in patients with sporadic dMMR colon cancer. Additional studies are needed to validate these results in metastatic disease.
- || Trial completion date, Trial primary completion date, Combination therapy, Metastases: PanCO: A Pilot Study of OncoSil (clinicaltrials.gov) - Sep 16, 2020
P=N/A, N=50, Active, not recruiting, Sponsor: OncoSil Medical Limited
Additional studies are needed to validate these results in metastatic disease. Trial completion date: Aug 2020 --> Feb 2021 | Trial primary completion date: Aug 2020 --> Nov 2020
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion date, Trial primary completion date, Metastases: Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Sep 16, 2020
P2, N=46, Recruiting, Sponsor: National Health Research Institutes, Taiwan
Trial completion date: Aug 2020 --> Feb 2021 | Trial primary completion date: Aug 2020 --> Nov 2020 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jun 2020 --> Dec 2021
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Phase classification, Enrollment change, Mismatch repair: CheckMate 8HW: A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Sep 15, 2020
P3, N=748, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jun 2020 --> Dec 2021 Phase classification: P3b --> P3 | N=494 --> 748
- leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., paclitaxel / Generic mfg.
[VIRTUAL] Signet Ring Cell Carcinoma in the Hispanic Population: A Case Series () - Sep 15, 2020 - Abstract #ACG2020ACG_3522;
Started on oxaliplatin, leucovorin and 5-fluororuacil...The patient started on Taxol 80 and Ramucirumab every two weeks, requiring monthly paracentesis...Patient started on folinic acid and fluorouracil...High PDL-1 expression is related to better target for treatment. These genes may be more prevalent in the Hispanic population, and should be furthered studied to see if SRCC can be prevented.
- leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg.
[VIRTUAL] A Minor Hiccup Unveiling a Devastating Stage IV Esophageal Adenocarcinoma () - Sep 15, 2020 - Abstract #ACG2020ACG_1572;
When present, dysphagia indicates advanced disease. Since the signs and symptoms of esophageal cancer are often subtle and nonspecific, recognition of hiccups as potential sign of esophageal cancer may play a role in early diagnosis and treatment.
- leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg.
[VIRTUAL] Right Lower Quadrant Abdominal Pain: Time to Think Beyond Acute Appendicitis () - Sep 15, 2020 - Abstract #ACG2020ACG_1221;
Diagnosis and management of GCC is challenging due to unpredictable biological behavior and scarcity of data. Guidelines about extent of surgical resection, role of chemotherapy, follow up protocol and role of aggressive peritoneal management need to be elucidated with prospective trial studies.
- Avastin (bevacizumab) / Roche
[VIRTUAL] Synchronous Non-Hereditary Esophageal and Colorectal Cancer in a Young, Healthy Male Patient () - Sep 15, 2020 - Abstract #ACG2020ACG_1083;
No guidelines are available for the treatment of MPMN; each patient should be considered individually, preferably by a multidisciplinary team. The type of each malignancy, the stage of the disease, and the patient’s overall health should be considered.
- leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg.
[VIRTUAL] Hepatoid Adenocarcinoma () - Sep 15, 2020 - Abstract #ACG2020ACG_870;
Repeated imaging revealed disease progression, she was then switched to folinic acid, fluorouracil, and oxaliplatin but her disease further progressed...Patient was treated with capecitabine and gemcitabine...When patients are not surgical candidates or disease is nonresectable; tyrosinase kinase inhibitors can play a role in treatment. It is important to increase the awareness of HAC which can lead to early diagnosis and early intervention for those affected with HAC.
- | Blincyto (blinatumomab) / Astellas, Amgen, Opdivo (nivolumab) / BMS
New P2 trial, Checkpoint inhibition: AALL1821: A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov) - Sep 13, 2020
P2, N=550, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- || leucovorin calcium / Generic mfg., Folotyn (pralatrexate) / Aurobindo
Clinical, Journal: Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate. (Pubmed Central) - Sep 13, 2020
The response rates were similar to those previously reported in CTCL and PTCL. The addition of leucovorin reduced the incidence of mucositis in patients with CTCL and PTCL.
- leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., paclitaxel / Generic mfg.
[VIRTUAL] Outcome of Locally Advanced Esophageal Cancer Patients Treated with Perioperative Chemotherapy and Chemoradiotherapy Followed by Surgery (Poster Hall) - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_1801;
A trend towards improved recurrence-free survival in patients with CTRT compared to PCT. There was no difference in outcome between patients receiving 41 Gy versus 45 Gy or more.
- leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., paclitaxel / Generic mfg.
[VIRTUAL] Neoadjuvant versus Postoperative Chemoradiotherapy in Gastric Cancer (Poster Hall) - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_1750;
NCRT was associated with a higher rate of R0 resection and longer OS with a lower toxicity compared to postCRT. Our findings suggest NCRT is superior to postCRT and support randomized trials to establish the optimal timing of CRT in gastric cancer.
- || fluorouracil topical / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. (Pubmed Central) - Sep 13, 2020
P1/2, P2
However, acquired resistance to therapy can emerge in some patients. Next-generation TRK inhibitors such as selitrectinib are currently in development to overcome this resistance (NCT02576431; NCT03215511).
- || leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., irinotecan / Generic mfg.
Biomarker, Clinical, Journal: Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. (Pubmed Central) - Sep 12, 2020
Preoperative FOLFIRINOX followed by chemoradiation for high-risk borderline resectable PDAC was associated with a resection rate of 45% and median OS of approximately 2 years. Our imaging-based biomarker validation indicates that personalized treatment may be achieved using these biomarkers at baseline and post-treatment.
- || Clinical, Journal: The resolution of carotid arterial thrombus by oral anticoagulation after IV thrombolysis for chemotherapy-induced stroke: A case report. (Pubmed Central) - Sep 11, 2020
Thrombolytic and anticoagulant medications in this patient suggested the thrombus formation with fibrin-rich content which may be attributable to both cancer and chemotherapy. Dabigatran, an oral anticoagulant, had a benefit for this subtype of ischemic stroke among patients with cancer.
- ||| Enrollment closed: OPRA: Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management (clinicaltrials.gov) - Sep 11, 2020
P2, N=358, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Dabigatran, an oral anticoagulant, had a benefit for this subtype of ischemic stroke among patients with cancer. Recruiting --> Active, not recruiting
- || ompenaclid (RGX-202) / Inspirna, EMD Serono
Trial completion date, Trial primary completion date, Combination therapy, Metastases: RGX-202-001: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer (clinicaltrials.gov) - Sep 10, 2020
P1, N=60, Recruiting, Sponsor: Rgenix, Inc.
Recruiting --> Active, not recruiting Trial completion date: Apr 2021 --> May 2022 | Trial primary completion date: Jul 2020 --> Mar 2021
- | Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open, Trial primary completion date, Metastases: TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. (clinicaltrials.gov) - Sep 10, 2020
P3, N=202, Recruiting, Sponsor: GCS IHFB Cognacq-Jay
Trial completion date: Apr 2021 --> May 2022 | Trial primary completion date: Jul 2020 --> Mar 2021 Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2021 --> Oct 2022
- | Enrollment closed, Trial completion date: Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Sep 10, 2020
P2, N=50, Active, not recruiting, Sponsor: Nagoya University
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2021 --> Oct 2022 Enrolling by invitation --> Active, not recruiting | Trial completion date: Jun 2020 --> Jun 2023
- || leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., irinotecan / Generic mfg.
Clinical, P2 data, Journal: Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201. (Pubmed Central) - Sep 9, 2020
Nonetheless, distribution of treatment effects on PFS did not vary with expression. For all patients and for those with low ERCC1 expression, FOLFOX was superior in efficacy to IT.
- | Trial completion date, Trial primary completion date: A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 9, 2020
P2, N=39, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
For all patients and for those with low ERCC1 expression, FOLFOX was superior in efficacy to IT. Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Metastases: D6070C00005: MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. (clinicaltrials.gov) - Sep 9, 2020
P1b/2, N=339, Active, not recruiting, Sponsor: MedImmune LLC
Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022